New drug aims to limit heart damage after a heart attack
Disease control
Recruiting now
This study tests a medicine called Xolatryp in 300 adults who have had a severe heart attack (STEMI) and are getting a procedure to open blocked arteries. Participants receive either a single 6-hour infusion of Xolatryp or a placebo (no active drug). The goal is to see if Xolatry…
Phase: PHASE2 • Sponsor: Nyrada Pty Ltd • Aim: Disease control
Last updated May 15, 2026 11:40 UTC